DMK PHARMACEUTICALS CORPORATION Restricted Stock or Unit Expense
DMK PHARMACEUTICALS CORPORATION reported Restricted Stock or Unit Expense of $1.87 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestrictedStockExpense · last filed 2022-03-31
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for the quarter ending 2020-12-31 was $750.00K.
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for the quarter ending 2020-09-30 was $829.00K, a 910.98% increase year-over-year.
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for the quarter ending 2020-06-30 was $823.00K, a 6.69% decline year-over-year.
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for the quarter ending 2019-09-30 was $82.00K.
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for fiscal 2021 was $1.87M, a 41.38% decline from fiscal 2020.
- DMK PHARMACEUTICALS CORPORATION restricted stock or unit expense for fiscal 2020 was $3.19M.
| Period end | Restricted Stock or Unit Expense 3 month | Restricted Stock or Unit Expense 6 month | Restricted Stock or Unit Expense 9 month | Restricted Stock or Unit Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.87M 10-K · filed 2022-03-31 | |||
| 2020-12-31 | $750.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.58M derived: sum of 2 quarters · filed 2022-03-31 | $2.40M derived: sum of 3 quarters · filed 2022-03-31 | $3.19M 10-K · filed 2022-03-31 |
| 2020-09-30 | $829.00K 10-Q · filed 2020-11-09 | $1.65M derived: sum of 2 quarters · filed 2020-11-09 | $2.44M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $823.00K 10-Q · filed 2020-08-17 | $1.61M 10-Q · filed 2020-08-17 | ||
| 2019-09-30 | $82.00K 10-Q · filed 2020-11-09 | $964.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.77M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $882.00K 10-Q · filed 2020-08-17 | $1.68M 10-Q · filed 2020-08-17 |